Recent progress of Src family kinase inhibitors as anticancer agents

被引：18

作者：

Cao, Xin ^{[1
]}

You, Qi-Dong ^{[1
]}

Li, Zhi-Yu ^{[1
]}

Wang, Xiao-Jian ^{[1
]}

Lu, Xiao-Yun ^{[1
]}

Liu, Xiao-Rong ^{[1
]}

Xu, Dan ^{[1
]}

Liu, Bao ^{[1
]}

机构：

[1] China Pharmaceut Univ, Dept Med Chem, Jiangsu Key Lab Carcinogenesis & Intervent, Nanjing 210009, Jiangsu, Peoples R China

来源：

MINI-REVIEWS IN MEDICINAL CHEMISTRY | 2008年 / 8卷 / 10期

基金：

中国国家自然科学基金;

关键词：

protein tyrosine kinases; Src family kinases; kinase domain; inhibitor; anticancer; drug design; SH2; SH3;

D O I：

10.2174/138955708785740634

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Src family of protein tyrosine kinases (SFKs) play key roles in regulating signal transduction in cellular processes. However, hyper-activated SFKs lead to uncontrolled cell proliferation and cancers. Many SFKs inhibitors were designed and synthesized as anticancer agents in the past several years and great progress has been made. Herein, some predominant examples of SFKs inhibitors recently developed are reviewed and special attentions are paid to the most important ATP binding site inhibitors.

引用

页码：1053 / 1063

页数：11

共 82 条

[71]

TITSCH C, 2005, CANCER RES, V65, P5358

[72]

Tsatsanis C, 2000, INT J MOL MED, V5, P583

[73]

Verbeek BS, 1996, J PATHOL, V180, P383, DOI 10.1002/(SICI)1096-9896(199612)180:4<383::AID-PATH686>3.0.CO

[74]

2-N

[75] Src inhibits adriamycin-induced senescence and G2 checkpoint arrest by blocking the induction of p21waf1 [J].

Vigneron, A ;

Roninson, IB ;

Gamelin, E ;

Coqueret, O .

CANCER RESEARCH, 2005, 65 (19) :8927-8935

[76] Inhibitors of Src tyrosine kinase: The preparation and structure-activity relationship of 4-anilino-3-cyanoquinolines and 4-anilinoquinazolines [J].

Wang, YD ;

Miller, K ;

Boschelli, DH ;

Ye, F ;

Wu, BQ ;

Floyd, MB ;

Powell, DW ;

Wissner, A ;

Weber, JM ;

Boschelli, F .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2000, 10 (21) :2477-2480

[77] Activated Src protein tyrosine kinase is overexpressed in late-stage human ovarian cancers [J].

Wiener, JR ;

Windham, TC ;

Estrella, VC ;

Parikh, NU ;

Thall, PF ;

Deavers, MT ;

Bast, RC ;

Mills, GB ;

Gallick, GE .

GYNECOLOGIC ONCOLOGY, 2003, 88 (01) :73-79

[78] 4-Anilino-6,7-dialkoxyquinolime-3-carbonitrile inhibitors of epidermal growth factor receptor kinase and their bioisosteric relationship to the 4-anilino-6,7-dialkoxyquinazoline inhibitors [J].

Wissner, A ;

Berger, DM ;

Boschelli, DH ;

Floyd, MB ;

Greenberger, LM ;

Gruber, BC ;

Johnson, BD ;

Mamuya, N ;

Nilakantan, R ;

Reich, MF ;

Shen, R ;

Tsou, HR ;

Upeslacis, E ;

Wang, YF ;

Wu, BQ ;

Ye, F ;

Zhang, N .

JOURNAL OF MEDICINAL CHEMISTRY, 2000, 43 (17) :3244-3256

[79] SOLUTION STRUCTURE OF THE SH3 DOMAIN OF SRC AND IDENTIFICATION OF ITS LIGAND-BINDING SITE [J].

YU, HT ;

ROSEN, MK ;

SHIN, TB ;

SEIDELDUGAN, C ;

BRUGGE, JS ;

SCHREIBER, SL .

SCIENCE, 1992, 258 (5088) :1665-1668

[80] 4-anilino-3-cyanobenzo[g]quinolines as kinase inhibitors [J].

Zhang, N ;

Wu, BQ ;

Wissner, A ;

Powell, DW ;

Rabindran, SK ;

Kohler, C ;

Boschelli, F .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2002, 12 (03) :423-425

← 1 2 3 4 5 6 7 8 9 →